Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients

Hemodialysis International

Volumn 15, Issue 1, 2011, Pages 95-99

  How, Priscilla P ^a   Anattiwong, Prathana ^a   Mason, Darius L ^a   Arruda, Jose A ^b   Lau, Alan H ^a  

^a Pharmacy Department   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Hemodialysis; Hyperphosphatemia; Lanthanum; Mineral and bone disorder; Phosphate binders

Indexed keywords

LANTHANUM CARBONATE; PHOSPHATE; PHOSPHATE BINDING PROTEIN; LANTHANUM; PHOSPHORUS; TABLET;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG BINDING; DRUG FORMULATION; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MALE; MEAL; NAUSEA; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VOMITING; ANALYSIS; BLOOD; HEMODIALYSIS; HYPERPARATHYROIDISM, SECONDARY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES; TABLET;

ADMINISTRATION, ORAL; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; LANTHANUM; MALE; MIDDLE AGED; PHOSPHATES; PHOSPHORUS; RENAL DIALYSIS; TABLETS;

EID: 79251550437     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2010.00509.x     Document Type: Article

References (15)

1. Chiang SS, Chen JB, Yang WC. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol. 2005; 63:461-470.
2. Finn WF, Joy MS, Hladik G, Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol. 2004; 62:193-201.
3. Joy MS, Finn WF, LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003; 42:96-107.
4. D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. 2003; 85 (Suppl):S73-S78.
5. ® (Lanthanum Carbonate). Wayne, PA: Shire US Inc.; 2005.
6. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351:1296-1305.
7. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res. 2002; 17:2094-2105.
8. Finn WF, SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: Safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol. 2006; 65:191-202.
9. Hutchinson AJ, Maes B, Vanwalleghem J, et al. Long term efficacy and tolerability of lanthanum carbonate: Results from a 3-year study. Nephron Clin Pract. 2006; 102:c61-c71.
10. Hutchinson AJ, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005; 100:c8-c19.
11. Navaneethan SD, Palmer SC, Craig JC, et al. Benefits and harms of phosphate binders in CKD: A systematic review of randomized controlled trials. Am J Kidney Dis. 2009; 54:619-637.
12. Arenas MD, Rebello P, Malek T, et al. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. J Nephrol. 2010; 23:683-692.
13. How P, Mason D, Arruda J, et al. Efficacy of chewed vs. crushed lanthanum on phosphorus binding in healthy volunteers. Clin Nephrol. 2010; 73:370-373.
14. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42 (Suppl 3):S1-S201.
15. Moe SM, Drüeke TB, Block GA, et al. Kidney disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; 113:S1-S130.